Edition:
United States

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

153.70USD
17 Aug 2017
Change (% chg)

-- (--)
Prev Close
$153.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
115,561
52-wk High
$157.36
52-wk Low
$95.16

Latest Key Developments (Source: Significant Developments)

Abiomed reports Q1 EPS $0.82
Thursday, 27 Jul 2017 07:22am EDT 

July 27 (Reuters) - Abiomed Inc :Abiomed announces Q1 FY 2018 revenue of $132.5 million, up 29 pct over prior year.Q1 GAAP earnings per share $0.82.Q1 revenue $132.5 million versus I/B/E/S view $130.9 million.Q1 earnings per share view $0.42 -- Thomson Reuters I/B/E/S.  Full Article

Abiomed Q1 gaap earnings per share $0.82
Thursday, 27 Jul 2017 07:00am EDT 

July 27 (Reuters) - Abiomed Inc ::Abiomed announces Q1 FY 2018 revenue of $132.5 million, up 29% over prior year.Q1 gaap earnings per share $0.82.Q1 revenue $132.5 million versus I/B/E/S view $130.9 million.Q1 earnings per share view $0.42 -- Thomson Reuters I/B/E/S.Abiomed Inc - company is increasing lower end of its fiscal year 2018 revenue guidance by $5 million to a new range of $560 million to $575 million.Abiomed Inc - company is maintaining its fiscal year guidance for GAAP operating margin in range of 22% to 24%.FY 2018 revenue view $570.4 million -- Thomson Reuters I/B/E/S.  Full Article

Abiomed Q4 gaap earnings per share $0.33
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Abiomed Inc :Abiomed announces Q4 fy 2017 revenue of $124.7 million, up 33% over prior year and total year revenue of $445.3 million, up 35% over prior year.Q4 gaap earnings per share $0.33.Q4 revenue $124.7 million versus i/b/e/s view $122.5 million.Q4 earnings per share view $0.35 -- Thomson Reuters I/B/E/S.Sees fy 2018 revenue up 25 to 29 percent.Sees fy 2018 revenue $555 million to $575 million.Fy2018 revenue view $574.3 million -- Thomson Reuters I/B/E/S.Fiscal year 2018 guidance for gaap operating margin to be in range of 22% to 24%.  Full Article

Abiomed announces Q4 revenue of $124.7 million, up 33 pct
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Abiomed Inc :Abiomed announces q4 fy 2017 revenue of $124.7 million, up 33% over prior year and total year revenue of $445.3 million, up 35% over prior year.Q4 gaap earnings per share $0.33.Q4 revenue $124.7 million versus i/b/e/s view $122.5 million.Sees fy 2018 revenue up 25 to 29 percent.Sees fy 2018 revenue $555 million to $575 million.Q4 earnings per share view $0.35 -- Thomson Reuters I/B/E/S.Sees fiscal year 2018 guidance for gaap operating margin to be in range of 22% to 24%..Fy2018 earnings per share view $1.78, revenue view $574.3 million -- Thomson Reuters I/B/E/S.  Full Article

Abiomed Q3 earnings per share $0.34
Thursday, 26 Jan 2017 07:00am EST 

Abiomed Inc : Says increasing lower end of its fiscal year 2017 revenue guidance with new range of $440 million to $445 million . Fy2017 revenue view $443.9 million -- Thomson Reuters I/B/E/S . Abiomed Inc - projects revenue to be around $122 million for Q4 of fiscal 2017 . Q4 revenue view $124.7 million -- Thomson Reuters I/B/E/S . Abiomed inc - maintaining its fiscal year guidance for gaap operating margin in range of 18 pct to 20 pct . Abiomed announces q3 fy 2017 revenue of $114.7 million, up 34 pct over prior year . Q3 gaap earnings per share $0.34 . Q3 revenue $114.7 million versus I/B/E/S view $112.7 million . Q3 earnings per share view $0.29 -- Thomson Reuters I/B/E/S .Sees Q4 2017 revenue about $122 million.  Full Article

Abiomed Q3 GAAP earnings per share $0.34
Thursday, 26 Jan 2017 07:00am EST 

Abiomed Inc : Abiomed announces Q3 FY 2017 revenue of $114.7 million, up 34% over prior year . Q3 GAAP earnings per share $0.34 . Q3 revenue $114.7 million versus I/B/E/S view $112.7 million . Q3 earnings per share view $0.29 -- Thomson Reuters I/B/E/S . Sees Q4 2017 revenue about $122 million . Increasing lower end of fiscal year 2017 revenue guidance with new range of $440 million to $445 million . Maintaining its fiscal year guidance for GAAP operating margin in range of 18% to 20% .FY2017 revenue view $443.9 million -- Thomson Reuters I/B/E/S.  Full Article

Abiomed announces 34 pct rise in preliminary Q3 revenue of $114.7 mln
Monday, 9 Jan 2017 04:01pm EST 

Abiomed Inc - : Abiomed announces preliminary Q3 FY 2017 revenue of $114.7 million, up 34% over prior year . Sees FY 2017 revenue $435 million to $445 million . Q3 revenue $114.7 million versus I/B/E/S view $113.4 million . Abiomed Inc says preliminary unaudited U.S. revenue from Impella products for Q3 grew 34% to approximately $100.3 million from $75.0 million in prior fiscal year . Abiomed Inc says for Q3 of fiscal 2017, U.S. patient usage grew 32% in comparison with same period of fiscal 2016 . Fy2017 earnings per share view $1.13, revenue view $444.7 million -- Thomson Reuters I/B/E/S .Q3 earnings per share view $0.29, revenue view $113.4 million -- Thomson Reuters I/B/E/S.  Full Article

Abiomed announces preliminary q3 preliminary revenue
Monday, 9 Jan 2017 04:01pm EST 

Abiomed Inc : Abiomed announces preliminary q3 fy 2017 revenue of $114.7 million, up 34% over prior year . Q3 revenue $114.7 million versus i/b/e/s view $113.4 million . Sees fy 2017 revenue $435 million to $445 million . Abiomed Inc - is maintaining its fiscal year 2017 revenue guidance of $435 million to $445 million . Abiomed Inc - also maintaining its fiscal year guidance for gaap operating margin to be in range of 18% to 20% .Abiomed Inc - qtrly preliminary unaudited u.s. Revenue from impella products grew 34% to approximately $100.3 million.  Full Article

Abiomed's Impella CP receives expanded FDA approval for high-risk PCI procedures
Wednesday, 7 Dec 2016 07:00am EST 

Abiomed Inc :Abiomed Impella CP receives expanded FDA approval for high-risk percutaneous coronary intervention (PCI) procedures.  Full Article

Abiomed Impella CP receives expanded FDA approval for high-risk percutaneous coronary intervention (PCI) procedures
Wednesday, 7 Dec 2016 07:00am EST 

Abiomed Inc : Has expanded FDA pre-market approval for impella heart pump use in PCI to include impella cp heart pump .Abiomed impella cp receives expanded FDA approval for high-risk percutaneous coronary intervention (PCI) procedures.  Full Article

BRIEF-Abiomed Q1 gaap earnings per share $0.82

* Abiomed announces Q1 FY 2018 revenue of $132.5 million, up 29% over prior year